Asia Pacific Fertility Supplements Market Size, Share & Industry Trends Analysis Report By Ingredient, By End-Use (Women and Men), By Distribution Channel, By Product (Capsules, Tablets, Soft Gels, Powder, and Liquid), By Country and Growth Forecast, 2022 - 2028

The Asia Pacific Fertility Supplements Market should witness market growth of 7.9% CAGR during the forecast period (2022-2028).

Numerous systemic and gynecological diseases, such as polycystic ovarian syndrome (PCOS), premature ovarian failure, endometriosis, and pelvic inflammatory disease, can have an impact on the female reproductive system and could result in infertility. In addition to organic illnesses, lifestyle elements including an improper diet and unbalanced nutrition can affect how women's bodies naturally reproduce.

Ovulatory dysfunction represents the most often occurring cause of female infertility. About 25% of diagnoses for infertility are related to ovulatory problems, and 70% of women who experience anovulation have PCOS. Such a disease is a multifactorial condition that is defined by ovarian morphological, biochemical (excessive luteinizing and androgen hormone concentrations), and clinical (hyperandrogenism and anovulation) characteristics.

Some of the most frequent health issues that several young couples in the region have had to deal with recently is infertility. A few of the variables that cause infertility and lead some people to turn to in vitro fertilization are sedentary lifestyles with very little physical activity, rising stress levels, and erratic sleep habits. In accordance with the Indian Society of Assisted Reproduction, a staggering number of Indians struggle with infertility, with rates higher in urban areas where one in every six couples has the problem.

The China market dominated the Asia Pacific Fertility Supplements Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $211.9 million by 2028. The Japan market is experiencing a CAGR of 7.3% during (2022-2028). Additionally, The India market would showcase a CAGR of 8.6% during (2022-2028).

Based on Ingredient, the market is segmented into Synthetic/ Blend of Natural & Synthetic and Natural. Based on End-Use, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Over-the-counter and Prescribed. Based on Product, the market is segmented into Capsules, Tablets, Soft Gels, Powder, and Liquid. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Fairhaven Health, Coast Science LLC, LENUS Pharma GesmbH, CellOxess LLC, Orthomol pharmazeutische Vertriebs GmbH, Exeltis USA, Inc. (Grupo INSUD), Yad-Tech, Bionova Lifesciences (Pragati Biocare Pvt. Ltd.), Vitabiotics Ltd., and TTK Healthcare Limited.

Scope of the Study

By Ingredient

• Synthetic/ Blend of Natural & Synthetic
• Natural

By End-use

• Women
• Men

By Distribution Channel

• Over-the-counter
• Prescribed

By Product

• Capsules
• Tablets
• Soft Gels
• Powder
• Liquid

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Fairhaven Health
• Coast Science LLC
• LENUS Pharma GesmbH
• CellOxess LLC
• Orthomol pharmazeutische Vertriebs GmbH
• Exeltis USA, Inc. (Grupo INSUD)
• Yad-Tech
• Bionova Lifesciences (Pragati Biocare Pvt. Ltd.)
• Vitabiotics Ltd.
• TTK Healthcare Limited

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free